CN Patent

CN107530307A — 包含etc1002和依泽替米贝的固定剂量组合和制剂以及治疗心血管疾病或降低心血管疾病风险的方法

Assigned to Esperion Therapeutics Inc · Expires 2018-01-02 · 8y expired

What this patent protects

本文公开的是包含固定剂量的ETC‑1002和依泽替米贝的组合物。本文还公开了用于使用固定剂量的ETC‑1002和依泽替米贝的方法。用途包括治疗受试者的心血管疾病或降低受试者的心血管疾病风险的方法。用途还包括治疗受试者的高胆固醇血症的方法。

USPTO Abstract

本文公开的是包含固定剂量的ETC‑1002和依泽替米贝的组合物。本文还公开了用于使用固定剂量的ETC‑1002和依泽替米贝的方法。用途包括治疗受试者的心血管疾病或降低受试者的心血管疾病风险的方法。用途还包括治疗受试者的高胆固醇血症的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN107530307A
Jurisdiction
CN
Classification
—
Expires
2018-01-02
Drug substance claim
No
Drug product claim
No
Assignee
Esperion Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.